In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Benevolent AI's net current asset value per share for the quarter that ended in Dec. 2023 was €0.58.
The historical rank and industry rank for Benevolent AI's Net Current Asset Value or its related term are showing as below:
XAMS:BAI'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.91 Med: 2.45 Max: 3.04
Current: 0.91
During the past 6 years, the highest Price-to-Net-Current-Asset-Value Ratio of Benevolent AI was 3.04. The lowest was 0.91. And the median was 2.45.
XAMS:BAI's Price-to-Net-Current-Asset-Value is ranked better than 90.07% of 1027
companies
in the Biotechnology industry
Industry Median: 3.88
vs XAMS:BAI: 0.91
Benevolent AI Net Current Asset Value Historical Data
The historical data trend for Benevolent AI's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benevolent AI's Net Current Asset Value
For the Biotechnology subindustry, Benevolent AI's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benevolent AI's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benevolent AI's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Benevolent AI's Price-to-Net-Current-Asset-Value falls into.
Benevolent AI Net Current Asset Value Calculation
Benevolent AI's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benevolent AI (XAMS:BAI) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Benevolent AI Net Current Asset Value Related Terms
Thank you for viewing the detailed overview of Benevolent AI's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XAMS:BAI has been successfully added to your 